公开(公告)号：EP1527083A1

公开(公告)日：2005-05-04

申请号：EP03740352.4

申请日：2003-06-26

申请人： Aventis Pharma Deutschland GmbH

发明人： BIGOT, Antony ,  STENGELIN, Siegfried ,  JÄHNE, Gerhard ,  HERLING, Andreas ,  MÜLLER, Günter ,  HOCK, Franz, Jakob ,  MYERS, Michael, R.

IPC分类号： C07H19/167 ,  A61K31/70

CPC分类号： C07H19/16

摘要： The present invention relates to compounds according to the general formula (I), wherein R1, A, B, Q, T, W and X have the meanings given in the description. These compounds are useful for the manufacture of a medicament for the treatment of insulin resistance, type 2 diabetes, metabolic syndrome, lipid disorders or cardiovasular disease or for providing an anti-lipolytic effect.

公开(公告)号：EP1404338A1

公开(公告)日：2004-04-07

申请号：EP02769485.0

申请日：2002-05-14

申请人： Aventis Pharma Deutschland GmbH

发明人： HERLING, Andreas ,  JÄHNE, Gerhard ,  MYERS, Michael, R. ,  MAGUIRE, Martin, P. ,  SPADE, Alfred, P. ,  EWING, William, R. ,  PAULS, Henry, W. ,  CHOI-SLEDESKI, Yong-Mi

IPC分类号： A61K31/52 ,  A61P3/10

CPC分类号： A61K31/52

摘要： The invention relates to the use of adenosine compounds described by formula (I) and certain derivatives thereof for producing a medicine for the treatment of the insulin resistance syndrome and diabetes. In formula (I), K is N, NO, or CH; Q is CH2 or O; R6 is hydrogen, alkyl, allyl, 2-methallyl, 2-butenyl, or cycloalkyl; X is (a) or (b); E is O or S; Y is e.g. hydrogen, alkyl, aralkyl, aryl; n and p are independently 0, 1, 2 or 3 provided that n + p is at least 1; T is e.g. hydrogen, alkyl, acyl, thioacyl, halo, carboxyl; R1, R2 and R3 are independently H, alkyl, or cycloalkyl; A is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR'; B is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR'; R' and R' are e.g independently hydrogen, alkyl, aralkyl or carbamoyl.